Literature DB >> 21052069

Inside the microbial and immune labyrinth: totally gutted.

Thomas T Macdonald1.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 21052069     DOI： 10.1038/nm1110-1194

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  11 in total

Review 1.  Immunity, inflammation, and allergy in the gut.

Authors:  Thomas T Macdonald; Giovanni Monteleone
Journal:  Science       Date:  2005-03-25       Impact factor: 47.728

2.  Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.

Authors:  Walter Reinisch; Williem de Villiers; László Bene; László Simon; István Rácz; Seymour Katz; István Altorjay; Brian Feagan; Dennis Riff; Charles N Bernstein; Daniel Hommes; Paul Rutgeerts; Antoine Cortot; Michael Gaspari; May Cheng; Tillman Pearce; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2010-02       Impact factor: 5.325

3.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.

Authors:  R Atreya; J Mudter; S Finotto; J Müllberg; T Jostock; S Wirtz; M Schütz; B Bartsch; M Holtmann; C Becker; D Strand; J Czaja; J F Schlaak; H A Lehr; F Autschbach; G Schürmann; N Nishimoto; K Yoshizaki; H Ito; T Kishimoto; P R Galle; S Rose-John; M F Neurath
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

4.  Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.

Authors:  D W Hommes; T L Mikhajlova; S Stoinov; D Stimac; B Vucelic; J Lonovics; M Zákuciová; G D'Haens; G Van Assche; S Ba; S Lee; T Pearce
Journal:  Gut       Date:  2006-02-28       Impact factor: 23.059

5.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

6.  Anti-interleukin-12 antibody for active Crohn's disease.

Authors:  Peter J Mannon; Ivan J Fuss; Lloyd Mayer; Charles O Elson; William J Sandborn; Daniel Present; Ben Dolin; Nancy Goodman; Catherine Groden; Ronald L Hornung; Martha Quezado; Zhiqiong Yang; Markus F Neurath; Jochen Salfeld; Geertruida M Veldman; Ullrich Schwertschlag; Warren Strober
Journal:  N Engl J Med       Date:  2004-11-11       Impact factor: 91.245

7.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Richard N Fedorak; Ellen Scherl; Mark R Fleisher; Seymour Katz; Jewel Johanns; Marion Blank; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-07-17       Impact factor: 22.682

8.  A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Authors:  W Reinisch; D W Hommes; G Van Assche; J-F Colombel; J-P Gendre; B Oldenburg; A Teml; K Geboes; H Ding; L Zhang; M Tang; M Cheng; S J H van Deventer; P Rutgeerts; T Pearce
Journal:  Gut       Date:  2006-02-21       Impact factor: 23.059

9.  Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease.

Authors:  L Rovedatti; T Kudo; P Biancheri; M Sarra; C H Knowles; D S Rampton; G R Corazza; G Monteleone; A Di Sabatino; T T Macdonald
Journal:  Gut       Date:  2009-09-08       Impact factor: 23.059

10.  Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.

Authors:  Andrew Nesbitt; Gianluca Fossati; Marianne Bergin; Paul Stephens; Sue Stephens; Roly Foulkes; Derek Brown; Martyn Robinson; Tim Bourne
Journal:  Inflamm Bowel Dis       Date:  2007-11       Impact factor: 5.325
View more
  10 in total

1.  New cytokine targets in inflammatory bowel disease.

Authors:  Thomas T Macdonald
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-07

Review 2.  Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Lucio Liberato; Monia Marchetti; Paolo Biancheri; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 3.  Recent advances in understanding Crohn's disease.

Authors:  Antonio Di Sabatino; Laura Rovedatti; Francesca Vidali; Thomas Thornton Macdonald; Gino Roberto Corazza
Journal:  Intern Emerg Med       Date:  2011-05-08       Impact factor: 3.397

4.  Endotoxin-induced uveitis is primarily dependent on radiation-resistant cells and on MyD88 but not TRIF.

Authors:  J Kezic; S Taylor; S Gupta; S R Planck; H L Rosenzweig; J T Rosenbaum
Journal:  J Leukoc Biol       Date:  2011-05-24       Impact factor: 4.962

5.  Relationships among the concentrations of 25 inflammation-associated proteins during the first postnatal weeks in the blood of infants born before the 28th week of gestation.

Authors:  Alan Leviton; Elizabeth N Allred; Hidemi Yamamoto; Raina N Fichorova
Journal:  Cytokine       Date:  2011-11-30       Impact factor: 3.861

6.  The breadth and type of systemic inflammation and the risk of adverse neurological outcomes in extremely low gestation newborns.

Authors:  Karl C K Kuban; T Michael O'Shea; Elizabeth N Allred; Raina N Fichorova; Tim Heeren; Nigel Paneth; Deborah Hirtz; Olaf Dammann; Alan Leviton
Journal:  Pediatr Neurol       Date:  2014-10-16       Impact factor: 3.372

7.  Estradiol Has Differential Effects on Acute Colonic Inflammation in the Presence and Absence of Estrogen Receptor β Expression.

Authors:  Cameron M Armstrong; Kimberly F Allred; Brad R Weeks; Robert S Chapkin; Clinton D Allred
Journal:  Dig Dis Sci       Date:  2017-06-01       Impact factor: 3.199

8.  The oxysterol receptor LXRβ protects against DSS- and TNBS-induced colitis in mice.

Authors:  T Jakobsson; L-L Vedin; T Hassan; N Venteclef; D Greco; M D'Amato; E Treuter; J-Å Gustafsson; K R Steffensen
Journal:  Mucosal Immunol       Date:  2014-05-07       Impact factor: 7.313

9.  Systems approach to the study of brain damage in the very preterm newborn.

Authors:  Alan Leviton; Pierre Gressens; Olaf Wolkenhauer; Olaf Dammann
Journal:  Front Syst Neurosci       Date:  2015-04-14

10.  Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis.

Authors:  Paolo Biancheri; Martyn R Foster; Matthew C T Fyfe; Thomas T MacDonald; Sameer Sirohi; Yemisi Solanke; Eleanor Wood; Adele Rowley; Steve Webber; Claire A Walshe
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.